LILRB1 and cancer: In cancer immunotherapy, blocking the interaction between MHC-I and LILRB1 is considered a promising strategy to enhance the immune system to recognize and destroy cancer cells, thereby facilitating more effective phagocytosis and elimination of malignant cells (17).This interaction can send inhibitory signals that dampen immune responses, preventing the immune system from attacking cells displaying MHC-I, which can include cancer cells.